Most Recent Articles by Jason Hoffman, PharmD, RPh
Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative breast cancer.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.
More Articles by Jason Hoffman, PharmD, RPh
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|